Key facts
- Topo Therapeutics’s last known valuation is $137.6M (Dec 2024).
- It has raised $10.6M across 1 recorded rounds; the latest was Early Stage VC ($10.6M) in Dec 2024.
- Notable investors include SR One Capital Management, MRL Ventures Fund, The Column Group.
- Topo Therapeutics has filed 2 Form Ds with the SEC, most recently Dec 2024 ($10.6M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Topo Therapeutics
Funding rounds
1 roundsAbout Topo Therapeutics
Operator of small molecule therapeutics intended to accelerate transmembrane protein drug discovery. The company offers transporter and ion channel programs in protein purification, structural determination, and mechanistic assays, enabling hospitals to treat neurological and rare diseases by leveraging novel insights into protein structure and small molecule-protein interactions.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Website
- topo-tx.com/
- Ownership
- Privately Held (backing)
Topo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Topo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Topo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.